The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the United States with a Phase 3 trial that recently launched at UMSOM’s Center for Vaccine Development and Global Health (CVD).
{iframe}https://www.umaryland.edu/news/archived-news/february-2021/umb-study-novavax-vaccine-demonstrates-strong-immune-response.php{/iframe}